Episode Description
This episode features Neil Tween, CFO of Owlstone Medical, and his path from audit at Deloitte into biotech and life sciences.
He started in accounting, which gave him a strong foundation in public company reporting and SEC requirements. But what really pulled him was the science side and working on "novel things." That led him to roles where he could get closer to the business itself.
After a controllership role at a gaming company, he joined GW Pharmaceuticals and helped navigate a NASDAQ IPO and the shift from R&D into commercial scale.
What Owlstone Medical Is Working On
At Owlstone Medical, Neil is focused on non-invasive diagnostics using breath analysis to detect diseases like lung cancer and tuberculosis.
The idea is simple but powerful: reduce the need for invasive procedures like biopsies so more people get screened earlier.
Part of this work is supported by the Gates Foundation, especially around making diagnostics accessible and cost-effective in global markets, including Africa.
Diagnostics vs Therapeutics
One of the more interesting parts of the discussion is how different diagnostics are from therapeutics.
• Diagnostics tend to be a slower ramp with lower peak revenue
• But they often last longer and require less expensive clinical work
There's also a lot of uncertainty. Clinical timelines rarely go exactly as planned.
Neil described the CFO role here as more of a "cautious brake," someone who stress-tests assumptions and builds scenarios for things like slow patient recruitment or regulatory delays.
From Pre-Revenue to Commercial
A big theme was how things change once revenue starts showing up.
• Before approval, it's all scenario planning and probability weighting
• After approval, the focus shifts quickly to execution
Neil emphasized the importance of building a "war chest" that extends beyond just funding the clinical trial itself. In practice, companies need enough capital to absorb delays, analyze results, and fund follow-on work, not just reach the initial data readout.
One key point: once a product is approved, the clock starts ticking on exclusivity. Any delay in launch directly impacts the most valuable revenue window. This makes commercialization timing a high-stakes decision, where teams often need to invest ahead of certainty.
Building the Finance Function
Scaling finance isn't just about hiring more people.
• The UK has strong R&D talent
• But commercialization often requires very specific experience (US rebates, Medicare, Medicaid)
That usually means bringing in people who have done it before.
Timing those hires matters more than most people expect.
Neil also emphasized staying in close dialogue with the board and auditors during these transitions to keep things stable while the business is moving fast.
Key Takeaways
• Don't stay only in finance, get into the operations
• Get under the hood of the business
• Be able to explain the company as well as the technical teams
• Stay optimistic, but plan conservatively
• Protect the company's capital
• Work on things you actually find interesting
Chapter Summary
(00:01:00) From Deloitte to GW Pharmaceuticals and IPO experience
(00:05:51) Owlstone Medical and breath-based diagnostics
(00:11:12) Gates Foundation partnership and global health focus
(00:14:41) Why clinical timelines rarely go as planned
(00:22:24) Diagnostics vs therapeutics economics
(00:28:30) Hiring for commercialization and finance scaling
(00:37:09) Book recommendations and leadership advice
Resources
• Bad Blood by John Carreyrou
• The Curious Case of Mike Lynch by Katie Prescott
• Prisoners of Geography by Tim Marshall
Stay Updated:
Please visit Brio360 on other episodes and resources on driving value creation
Follow our host:
Peter Ho
https://linkedin.com/in/peterhocm
Know a great guest for Value Drivers? Pitch founders, CEOs, CFOs, operators, or investors with standout capital allocation and scaling stories: media@brio360.com
Please note that information provided in the podcast is for informational and educational purposes only and is not a recommendation to take any particular action, nor an offer or solicitation to buy or sell any securities or services presented. It is not investment advice. Brio360 does not provide legal or tax advice.